Product pharmaceutical-intermediates-nuclide-drug

Home > products > pharmaceutical-intermediates> nuclide-drug

Catalog	name	Description	price
R-M2z-9286	DBCO-PEG2000-DOTA-Gd	DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a chelating agent that binds to Gd3+ ions, which are used as contrast agents in MRI to enhance image quality. Gd (Gadolinium) is the paramagnetic element that, when chelated with compounds like DOTA, can significantly improve the visibility of tissues in MRI scans. This complex is designed to be used as a contrast agent to enhance the visibility of tissues or organs in MRI scans, aiding in the diagnosis and monitoring of various medical conditions.	price>
R-M2-9515	Gd-DOTA-C6	Gd-DOTA-C6/Gadolinium-DOTA-C6/C6-DOTA-Gd is a gadolinium-based contrast agent featuring DOTA as a chelator and a C6 functional group that likely enhances its properties for medical imaging applications, particularly in MRI. Its design reflects a balance between chemical stability, safety, and effectiveness in enhancing image contrast, contributing significantly to diagnostic imaging practices.	price>
R-M2-9965	Tb-DOTA-tuftsin	Tb-DOTA-tuftsin/Terbium-DOTA-tuftsin conjugates are likely to be a promising optical reagents as probes of the immune response with involvement of macrophage cells in a variety of diseases.Tb-DOTA-tuftsin is internalized by macrophages through a mechanism mediated by pro phagocytin receptors, and its pentapeptide analogue (Tb-DOTA-pentapeptide) has a higher affinity than intact pro phagocytin.It can be applied to targeting, optical imaging, and magnetic resonance imaging (MRI).	price>
R-M2-9966	Tb-DOTA-pentapeptide	Tb-DOTA-pentapeptide conjugates/Terbium-DOTA-pentapeptide are likely to be a promising optical reagents as probes of the immune response with involvement of macrophage cells in a variety of diseases.	price>
R-M2-9967	Gd-DOTA-tuftsin	Gd-DOTA-tuftsin/Gd-DOTA-tuftsin(Thr-Lys-Pro-Arg) is a biomarker formed by the binding of gadolinium (Gd) labeled DOTA chelates with tuftsin, mainly used for macrophage specific imaging, especially as a cell specific contrast agent in magnetic resonance imaging (MRI).Gd-DOTA-tuftsin is internalized by macrophages through a mechanism mediated by pro phagocytin receptors, and its pentapeptide analogs (such as Gd DOTA pentapeptide) have higher affinity.	price>
R-M2-9968	Gd-DOTA-pentapeptide	Gd-DOTA-pentapeptide is a molecular probe formed by the binding of gadolinium (Gd) labeled DOTA chelate with pentapeptide, mainly used for targeted magnetic resonance imaging (MRI). Its core function is to enhance imaging contrast by specifically binding to targets (such as tumor related molecules), achieving high-sensitivity detection of diseases. It can be applied to tumor imaging and vascular diseases. At present, Gd-DOTA derivatives (such as Gd-DOTApentapeptide) exhibit higher relaxation efficiency in liver targeted contrast agents, and the introduction of structures such as pyridine rings can reduce renal accumulation and improve safety.	price>
R-M2-9971	68Ga-DOTA-PA1	68Ga-DOTA-PA1 is a novel PET radiotracer, targeting multi-subtypes of SSTRs, and was confirmed to be useful for PET imaging. It may have potential as a noninvasive PET radiotracer for imaging SSTR-positive tumors.68Ga-DOTA-PA1 had high radiochemical yield and radiochemical purity of over 95% and 99%, respectively. PA1:new pan-somatostatin receptors (pan-SSTRs) probe PA1/new pan-SSTRs targeted precursor PA derivative (PA1)	price>
R-M2-9973	[64Cu]NOTA-PA1	[64Cu]NOTA-PA1 was obtained with high specific activity, high radiochemical purity, and good stability. [64Cu]NOTA-PA1 showed high binding affinity for SSTRs expressed in A549 cells.	price>
R-M2-10031	64Cu-PSMA-617	⁶⁴Cu-PSMA-617 is a radiolabeled prostate-specific membrane antigen (PSMA) targeting ligand used for PET imaging of prostate cancer. PSMA-617 is a clinically validated small-molecule ligand with high affinity for PSMA, and when labeled with Copper-64 (⁶⁴Cu), it enables sensitive, quantitative, and long-lived PET imaging. Applications: PET imaging of PSMA-positive prostate tumors; Monitoring tumor burden and metastasis; Biodistribution & pharmacokinetic studies; Tumor targeting validation for PSMA-based drug delivery systems; Companion diagnostic for PSMA-targeted radiotherapies.	price>
R-M2-10043	¹⁸F-PSMA-1007	¹⁸F-PSMA-1007 is a clinically used PSMA-targeted PET radiotracer for imaging prostate cancer. A key advantage of ¹⁸F-PSMA-1007 is low urinary activity, which improves lesion detection in the:prostate bed;pelvis;prostatectomy fossa;(where Ga-68-PSMA tracers can have bladder spillover signals).	price>

...